✦ LIBER ✦

Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958)

✍ Scribed by M.E.R O'Brien; T Splinter; E.F Smit; B Biesma; M Krzakowski; V.C.G Tjan-Heijnen; A Van Bochove; J Stigt; M.J.A Smid-Geirnaerdt; C Debruyne; C Legrand; G Giaccone

Book ID: 117660081
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 161 KB
Volume: 39
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(03)00319-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine and Cisplatin as induction r

Gemcitabine and Cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 Non-Small Cell Lung Cancer: A phase II study of the EORTC Lung Cancer Cooperative Group (EORTC 08955)

✍ Van Zandwijk, N; Smith, E.F; Kramer, G.W.P; Schramel, F; Gans, S; Festen, J; Ter 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Chemotherapy preceding surgery and radio

Chemotherapy preceding surgery and radiotherapy in non-small cell lung cancer (NSCLC) patients with biopsy-proven N2 disease: a phase II EORTC study

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Docetaxel and cisplatin as induction che

Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)

✍ B. Biesma; C. Manegold; H.J.M. Smit; L. Willems; C. Legrand; A. Passioukov; J.P. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Gemcitabine, paclitaxel, and cisplatin a

Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma : A phase II multicenter study

✍ Filippo De Marinis; Fabrizio Nelli; Maria Rita Migliorino; Olga Martelli; Enrico 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND The objective of the current study was to define the activity and tolerability, as well as the influence on resectability, of the combination of gemcitabine, paclitaxel, and cisplatin (GTP) as induction chemotherapy for patients with Stage IIIA(N2) nonsmall cell lung carc